《美国医学会杂志》第242卷第20期(1979年)医学新闻栏报道:生物学单克隆抗体技术最近已进入商业化。免疫学家们预言,这一技术将迅速大量生产极纯的和对抗原有高度选择性的抗体,应用于许多疾病(包括肿瘤)的诊断和治疗。他们认为,这一新的生物学技术将用于更精确的进行组织分型、提高器官移植的成功率。 Journal of the American Medical Association, Vol. 242, No. 20 (1979) Medical News Bar: Biological monoclonal antibody technology has recently become commercially available. Immunologists predict that the technology will rapidly mass-produce extremely pure antibodies to antigens that are highly selective and are used in the diagnosis and treatment of many diseases, including tumors. They believe that this new biological technology will be used to more accurately organize the type and improve the success rate of organ transplantation.